Arrowstreet Capital Limited Partnership Decreases Stake in Thermo Fisher Scientific Inc. $TMO

Arrowstreet Capital Limited Partnership reduced its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 31.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 867,512 shares of the medical research company’s stock after selling 398,613 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in Thermo Fisher Scientific were worth $502,680,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Atlas Capital Advisors Inc. acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $195,000. Altrafin AG acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $934,000. Cordoba Advisory Partners LLC acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $236,000. Kestra Advisory Services LLC raised its stake in shares of Thermo Fisher Scientific by 2.4% during the 4th quarter. Kestra Advisory Services LLC now owns 27,816 shares of the medical research company’s stock worth $16,118,000 after buying an additional 660 shares during the last quarter. Finally, Transamerica Financial Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 41.7% during the 4th quarter. Transamerica Financial Advisors LLC now owns 8,879 shares of the medical research company’s stock worth $5,145,000 after buying an additional 2,615 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 1.4%

NYSE TMO opened at $468.80 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99. The company has a 50-day moving average of $479.14 and a 200-day moving average of $527.68. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The company has a market cap of $174.22 billion, a P/E ratio of 25.77, a P/E/G ratio of 2.08 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. During the same quarter in the prior year, the company posted $5.15 EPS. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 24.85 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.34%.

Insider Activity at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This represents a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

TMO has been the subject of several research reports. Wolfe Research initiated coverage on Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price target for the company. DZ Bank initiated coverage on Thermo Fisher Scientific in a research note on Friday, March 27th. They set a “buy” rating and a $610.00 price target for the company. HSBC downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating and cut their price target for the stock from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Morgan Stanley reissued an “overweight” rating and issued a $620.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. Finally, Stifel Nicolaus cut their target price on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a research note on Friday, April 24th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $608.95.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.